Sera Prognostics (SERA)
NASDAQ:SERA
Want to see SERA full AI Analyst Report?
SERA Stock Chart & Stats
$2.30
$0.42(5.34%)
At close: 4:00 PM EST
$2.30
$0.42(5.34%)
Day’s Range― - ―
52-Week Range$1.56 - $4.09
Previous CloseN/A
Volume57.63K
Average Volume (3M)40.22K
Market Cap
$68.53M
Enterprise Value$70.51M
Total Cash (Recent Filing)$47.40M
Total Debt (Recent Filing)$2.50M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 12, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding38,190,968
10 Day Avg. Volume55,279
30 Day Avg. Volume40,220
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.86
Price to Sales (P/S)1735.84
P/FCF Ratio-5.34
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue1.24K
Enterprise Value/Gross Profit-646.89
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$6.00Price Target Upside160.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$415.33K
Bulls Say, Bears Say
Bulls Say
Multi-year Cash Runway & Cost CutsA multi-year cash runway through 2029 combined with a planned ~$10M annual cost reduction materially increases the company's ability to execute commercialization, payers and partnerships without imminent refinancing. This durable liquidity cushion supports multi‑year evidence and coverage timelines.
Partnership-driven Commercial RolloutExpanding partner programs and provider reach create repeatable, scalable distribution channels. A structured rollout (one program per quarter) builds durable institutional adoption, enables implementation learning, and creates a platform to convert payer discussions into sustained testing volume over time.
Clinical Evidence & Regulatory ProgressPeer-reviewed study publications plus planned health-economic and Medicaid outcomes strengthen clinical and economic value propositions. Progress toward CE Marking expands addressable markets and creates durable regulatory pathways supporting longer-term commercial adoption in Europe and payer acceptance.
Bears Say
Minimal, Declining Revenue And Negative Gross ProfitPersistent minimal revenue and negative gross profit indicate the business is currently loss-making at the unit level, limiting scalability. Until tests achieve volume, pricing, and cost efficiencies, margins will remain unfavorable and commercial progress may not translate to profitability.
Sustained Cash Burn And Negative Operating Cash FlowConsistent negative operating and free cash flows erode balance sheet resources over time and increase reliance on external financing. Even with current runway, ongoing cash burn constrains strategic flexibility and raises execution risk if commercial traction or reimbursement lags expectations.
Delayed Coverage Timelines & Limited Volume VisibilityReimbursement and adoption are multi-step and slow; a ~2‑year Medicaid timeline and absent test-volume KPIs create prolonged uncertainty about scalable revenue realization. This structural timing risk can delay breakeven and strain resources despite partnership progress.
Sera Prognostics News
SERA FAQ
What was Sera Prognostics’s price range in the past 12 months?
Sera Prognostics lowest stock price was $1.56 and its highest was $4.09 in the past 12 months.
What is Sera Prognostics’s market cap?
Sera Prognostics’s market cap is $68.53M.
When is Sera Prognostics’s upcoming earnings report date?
Sera Prognostics’s upcoming earnings report date is Aug 12, 2026 which is in 51 days.
How were Sera Prognostics’s earnings last quarter?
Sera Prognostics released its earnings results on May 06, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.167 by -$0.003.
Is Sera Prognostics overvalued?
According to Wall Street analysts Sera Prognostics’s price is currently Undervalued.
Does Sera Prognostics pay dividends?
Sera Prognostics does not currently pay dividends.
What is Sera Prognostics’s EPS estimate?
Sera Prognostics’s EPS estimate is -0.15.
How many shares outstanding does Sera Prognostics have?
Sera Prognostics has 38,190,968 shares outstanding.
What happened to Sera Prognostics’s price movement after its last earnings report?
Sera Prognostics reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.167. Following the earnings report the stock price went up 6.077%.
Which hedge fund is a major shareholder of Sera Prognostics?
Currently, no hedge funds are holding shares in SERA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sera Prognostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (160.87% Upside)
$6.00 (160.87% Upside)
Blogger Sentiment
Neutral
SERA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $87.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.89%
12-Months-Change
Fundamentals
Return on Equity
-41.02%
Trailing 12-Months
Asset Growth
-20.85%
Trailing 12-Months
Company Description
Sera Prognostics
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
SERA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong strategic progress on commercialization, payer engagement, media awareness, scientific publications and a clear plan to reduce operating expense that together support a multi-year commercial opportunity. However, near-term financials remain weak — Q1 revenue fell to $14k (down ~63% YoY), a continuing net loss (~$8.4M) and management expects 2026 revenue to be modest and uneven while payer coverage and broader adoption timelines play out. Given meaningful operational and evidence milestones but limited near-term revenue visibility, the tone is cautiously constructive but balanced by financial and timing risks.View all SERA earnings summariesSERA Stock 12 Month Forecast
Average Price Target
$6.00
▲(160.87% Upside)
Technical Analysis
Ownership Overview
5.35% Insiders
4.06% Mutual Funds
36.09% Other Institutional Investors
50.93% Public Companies and
Individual Investors